<DOC>
	<DOCNO>NCT01004822</DOCNO>
	<brief_summary>The purpose study determine CVX-241 ( PF-05057459 ) safe tolerable give weekly infusion adult patient advance solid tumor .</brief_summary>
	<brief_title>A Safety , Tolerability , And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study prematurely discontinue 14 September 2011 due significant pharmacological effect ( safety/PD/efficacy ) 25 mg/kg cohort , T1/2 base VEGF bind shorter expect current and/or high dos consider feasible development . There safety concern associate decision terminate program/study .</detailed_description>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Confirmed solid tumor unresponsive current therapy standard therapy . Stage 2 : Histologically cytologically document EOC PPC &lt; equal 3 previous anticancer therapy , least 1 prior platinum contain regimen . Adequate coagulation , liver , renal function . Candidate Dynamic ContrastEnhanced Magnetic Resonance Imaging [ DCEMRI ] evaluation Eastern Cooperative Oncology Group [ ECOG ] performance status 0 1 History clinically significant toxicity Vascular Endothelial Growth Factor [ VEGF ] inhibition . Evidence bleed problem . Uncontrolled hypertension . Patients primary brain cancer and/or nonsmall cell lung cancer squamous cell histology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Treatment Non-Randomized Single Group Assignment Safety Study Neoplasms Carcinoma Cancer Malignancy</keyword>
</DOC>